Incyte Corp (INCY) stock
INCYNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 13/3091% above fair value
$119.09−1.18 (-0.98%)
Close on Nov 17, 2026Market cap $24.27BP/E 63.3Yield –
Incyte price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Incyte's price to sales ratio was 4.2× on Nov 11, 2026, against 4.3× a year earlier. Over the last 5 years it ranged from 2.8× to 5.9×, with a median of 4.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 4.2× | +0.2 |
| 2025 | Dec 31, 2025 | 4.0× | +0.8 |
| 2024 | Dec 31, 2024 | 3.3× | −0.6 |
| 2023 | Dec 29, 2023 | 3.9× | −1.5 |
| 2022 | Dec 30, 2022 | 5.4× | −0.2 |
| 2021 | Dec 31, 2021 | 5.6× | −2.2 |
| 2020 | Dec 31, 2020 | 7.8× | −1.2 |
| 2019 | Dec 31, 2019 | 8.9× | +1.4 |
| 2018 | Dec 31, 2018 | 7.5× | −6.6 |
| 2017 | Dec 29, 2017 | 14.1× | −4.4 |
| 2016 | Dec 30, 2016 | 18.4× | −13.4 |
| 2015 | Dec 31, 2015 | 31.8× | +6.3 |
| 2014 | Dec 31, 2014 | 25.5× | −1.9 |
| 2013 | Dec 31, 2013 | 27.4× | +17.2 |
| 2012 | Dec 31, 2012 | 10.3× | −2.3 |
| 2011 | Dec 30, 2011 | 12.5× | −171.5 |
| 2010 | Dec 31, 2010 | 184.0× | – |
See a number that looks wrong?